Table 3.

Antimicrobial susceptibility and estimated carbapenemase rates among clinical isolates of Enterobacterales, NME and P. aeruginosa, by country during 2017–21

		% Susceptible												Estimated % carrying carbapenemasea
Organism	n	C/T	IPM/REL	MEM	IPMb,c	ETP	FEPc	CAZc	CRO	TZPc	LVXc,d	AMK	CST	MBL	KPC	OXA-48-like	GES
Enterobacterales
Belgium	2039	93.6	NA	99.1	98.5	97.0	83.3	76.7	76.7	80.5	80.9	97.9	83.8	0.5	0	0.9	0
Norway	495	97.4	NA	99.8	99.6	98.4	94.9	90.5	90.3	92.3	91.7	99.6	90.1	0	0	0	0
Sweden	778	97.4	NA	100	99.7	99.2	88.9	86.8	84.7	89.2	84.2	99.2	87.0	0.1	0	0	0
Switzerland	846	94.7	NA	99.6	99.5	98.5	92.2	85.5	84.5	87.1	89.1	99.3	83.1	0	0.1	0	0
NME
Belgium	1865	93.2	99.2	99.0	98.6	96.7	82.1	75.8	75.4	78.9	81.2	98.0	91.5	0.5	0	1.0	0
Norway	474	97.3	100	99.8	99.6	98.3	94.7	90.3	90.3	92.0	91.6	99.8	94.1	0	0	0	0
Sweden	716	97.2	99.9	100	99.7	99.2	88.3	86.2	84.1	88.4	83.8	99.2	94.6	0.1	0	0	0
Switzerland	778	94.2	100	99.6	99.6	98.3	91.5	84.7	83.8	86.0	89.5	99.2	90.1	0	0.1	0	0
P. aeruginosa
Belgium	360	94.2	93.9	81.4	80.8	NA	79.2	77.5	NA	75.6	83.1	92.8	100	2.7	0	0	0
Norway	42	100	97.6	81.0	83.3	NA	85.7	78.6	NA	78.6	85.7	100	100	0	0	0	0
Sweden	280	95.0	93.2	80.0	75.7	NA	79.3	77.9	NA	76.8	79.3	90.7	99.6	0	0	0	0
Switzerland	141	100	97.9	85.8	85.1	NA	87.2	85.8	NA	80.9	96.5	99.3	100	0	0	0	0

C/T, ceftolozane/tazobactam; IPM/REL, imipenem/relebactam; MEM, meropenem; ETP, ertapenem; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; TZP, piperacillin/tazobactam; LVX, levofloxacin; AMK, amikacin; CST, colistin; NA, not applicable or MIC breakpoint not available.

^aNo isolates carried both an MBL and another carbapenemase.

^bThe results provided for Enterobacterales combine % susceptible, increased exposure values for Morganellaceae and % susceptible values for NME.⁶

^cThe results provided for P. aeruginosa are % susceptible, increased exposure values.⁶

^dLevofloxacin was only tested against Enterobacterales isolates from 2018 to 2021.